Dow Jones

38 686,32

1,51%

DAX

Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

GMAB

Genmab AS (GMAB)

Genmab AS

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:GMAB

1 2 3 4 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
01/06/2024	16h00	Business Wire	Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)	NASDAQ:GMAB	Genmab AS
28/05/2024	17h29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
23/05/2024	23h00	Business Wire	Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:GMAB	Genmab AS
21/05/2024	17h10	Business Wire	Genmab Completes Acquisition of ProfoundBio	NASDAQ:GMAB	Genmab AS
14/05/2024	16h05	Business Wire	Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress	NASDAQ:GMAB	Genmab AS
30/04/2024	00h40	Business Wire	TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
30/04/2024	00h40	Business Wire	FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
03/04/2024	07h35	Business Wire	Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio	NASDAQ:GMAB	Genmab AS
01/03/2024	23h04	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:GMAB	Genmab AS
27/02/2024	13h45	Business Wire	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
22/02/2024	22h28	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:GMAB	Genmab AS
14/02/2024	19h49	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:GMAB	Genmab AS
02/02/2024	12h45	Business Wire	Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
09/01/2024	13h45	Dow Jones News	Pfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval	NASDAQ:GMAB	Genmab AS
09/01/2024	12h45	Business Wire	TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
09/01/2024	12h45	Business Wire	TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
09/12/2023	18h00	Business Wire	New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)	NASDAQ:GMAB	Genmab AS
09/12/2023	18h00	PR Newswire (US)	New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)	NASDAQ:GMAB	Genmab AS
27/11/2023	13h00	Business Wire	Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
02/11/2023	14h05	Business Wire	Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)	NASDAQ:GMAB	Genmab AS
22/10/2023	16h30	Business Wire	TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial	NASDAQ:GMAB	Genmab AS
25/09/2023	14h50	Dow Jones News	AbbVie, Genmab Get Conditional Europe OK of Tepkinly Lymphoma Drug	NASDAQ:GMAB	Genmab AS
25/09/2023	13h45	Business Wire	Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)	NASDAQ:GMAB	Genmab AS
25/09/2023	11h55	Business Wire	EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)	NASDAQ:GMAB	Genmab AS
04/09/2023	21h00	Business Wire	Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone	NASDAQ:GMAB	Genmab AS
04/09/2023	21h00	Business Wire	Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy	NASDAQ:GMAB	Genmab AS
21/07/2023	10h30	Business Wire	Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)	NASDAQ:GMAB	Genmab AS
28/06/2023	12h02	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:GMAB	Genmab AS
28/06/2023	01h48	Dow Jones News	AbbVie, Genmab Need Further Follow Up on Trial for Follicular Lymphoma Treatment	NASDAQ:GMAB	Genmab AS
28/06/2023	00h50	Business Wire	Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)	NASDAQ:GMAB	Genmab AS